Christophe Degois Email

VP Business Development . Oncolytics Biotech

Current Roles

Employees:
54
Revenue:
$4.2M
About
Oncolytics Biotech Inc. is developing pelareorep, a safe and well-tolerated intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments.
Oncolytics Biotech Address
4660 La Jolla Village Dr
Calgary, AB
United States
Oncolytics Biotech Email